On March 3, 2026, the Osaka District Court dismissed a patent infringement lawsuit seeking an injunction against a generic drug, addressing an unprecedented question regarding the scope of extended…
The lesson of this year's BIO International Convention in San Diego is not that the market has finally discovered the Unified Patent Court; it has been aware of it for some time. It is that life…
This week, I have the pleasure of speaking in Amsterdam at C5’s 19th Annual Forum on Pharma & Biotech Patent Litigation in Europe, in a panel devoted to running and defending preliminary injunctions…
This post is a continuation of the previous post published on July 25, 2025 and available here. Said post mentions case No. А40-315385/24 relating to osimertinib, in which the Russian pharmaceutical…
The EU Biotech Act is a legislative initiative aimed at simplifying biotech regulation, boosting innovation and investment, and strengthening Europe’s competitiveness and biotech ecosystem, which we…
BackgroundWe previously set out the background and genesis of the proposed regulatory provisions of the "Proposal for a Directive of the European Parliament and of the Council on the Union Code…
In a dramatic change to Australian patent law, Australia's Full Federal Court has just held that patents for pharmaceutical formulations are not eligible for patent term extensions (PTE): Otsuka…
Preliminary injunctions (“PIs”) matter in life sciences patent cases. As often as not, the party which prevails at this stage of the litigation will have the upper hand in settlement negotiations. …
The Russian Intellectual Property Court (IPC) recently revoked an extension (SPC) of Pfizer's Eurasian patent No. 012666 relating to the composition of tofacitinib in relation to the Russian…
